Skip to main content

Advertisement

Table 3 Drug exposure in patients with OS ≥24 versus < 24 months in the axitinib titration arm

From: Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study

Parameter OS ≥24 months n = 33 OS < 24 months n = 20a
Days on treatment,b median (range) 925 (106–1795) 85 (42–456)
Days on drug,c median (range) 925 (91–1688) 84 (38–456)
Average daily dose, median (range), mg 13.9 (4.9–23.4) 13.0 (9.9–19.2)
Relative dose intensity, median (range), % 135 (46–224) 125 (83–192)
Patients with dose decrease < 5 mg bid, n (%) 10 (30) 1 (5)
  1. Abbreviations: bid twice daily, OS overall survival
  2. aExcluded 3 patients who were censored < 24 months in OS
  3. bTime period starting from date of the first dose to date of the last dose or data cutoff
  4. cTotal number of days in which axitinib was actually administered